Sumitomo Dainippon Pharma Top Insiders

DNPUFDelisted Stock  USD 4.37  0.00  0.00%   
Sumitomo Dainippon employs about 7 K people. The company is managed by 10 executives with a total tenure of roughly 61 years, averaging almost 6.0 years of service per executive, having 698.7 employees per reported executive. Examination of Sumitomo Dainippon's management performance can provide insight into the company performance.
Hisayoshi Kashima  Director
Director of Accounting
Yoshiharu Ikeda  Director
Executive Officer, Chief Director of Technology Research
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Sumitomo Dainippon Management Team Effectiveness

Sumitomo Dainippon's management efficiency ratios could be used to measure how well Sumitomo Dainippon manages its routine affairs as well as how well it operates its assets and liabilities.

Sumitomo Dainippon Workforce Comparison

Sumitomo Dainippon Pharma is one of the top stocks in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 22,019. Sumitomo Dainippon totals roughly 6,987 in number of employees claiming about 32% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.03.

Sumitomo Dainippon Notable Stakeholders

A Sumitomo Dainippon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sumitomo Dainippon often face trade-offs trying to please all of them. Sumitomo Dainippon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sumitomo Dainippon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hisayoshi KashimaDirector of AccountingProfile
Yoshiharu IkedaExecutive Officer, Chief Director of Technology ResearchProfile
Hiroshi NomuraDirectorProfile
Hideyuki HaradaExecutive Officer, Chief Director of ResearchProfile
Shigeyuki NishinakaExecutive Officer, Director of Business DevelopmentProfile
Hiroyuki BabaExecutive OfficerProfile
Toru KimuraExecutive Officer, Manager of Regeneration & Cell Medicine Business Promotion OfficeProfile
Takuya TaguchiSr UnitProfile
Atsuko HiguchiExecutive OfficerProfile
Naoki NoguchiCorp GovernanceProfile

About Sumitomo Dainippon Management Performance

The success or failure of an entity such as Sumitomo Dainippon Pharma often depends on how effective the management is. Sumitomo Dainippon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sumitomo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sumitomo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Dai Nippon operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 6987 people.

Sumitomo Dainippon Workforce Analysis

Traditionally, organizations such as Sumitomo Dainippon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sumitomo Dainippon within its industry.

Sumitomo Dainippon Manpower Efficiency

Return on Sumitomo Dainippon Manpower

Revenue Per Employee80.2M
Revenue Per Executive56B
Net Income Per Employee8.1M
Net Income Per Executive5.6B
Working Capital Per Employee32.2M
Working Capital Per Executive22.5B
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Sumitomo Pink Sheet

If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bonds Directory
Find actively traded corporate debentures issued by US companies